Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43845   clinical trials with a EudraCT protocol, of which   7282   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2017-003770-14
    Sponsor's Protocol Code Number:3030-202-002
    National Competent Authority:Netherlands - Competent Authority
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-08-09
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedNetherlands - Competent Authority
    A.2EudraCT number2017-003770-14
    A.3Full title of the trial
    A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Participants (Age 6 to 17 Years) with Irritable Bowel Syndrome with Diarrhea (IBS-D)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Evaluate the Safety and Efficacy of Eluxadoline in Participants Age 6 to 17 Years with Irritable Bowel Syndrome with Diarrhea
    A.4.1Sponsor's protocol code number3030-202-002
    A.7Trial is part of a Paediatric Investigation Plan Yes
    A.8EMA Decision number of Paediatric Investigation PlanP/107/2020
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorAllergan LTD
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportAllergan Ltd
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationAllergan Ltd
    B.5.2Functional name of contact pointAllergan Ltd EU Regulatory Dept
    B.5.3 Address:
    B.5.3.1Street AddressMarlow International Parkway
    B.5.3.2Town/ cityMarlow / Buckinghamshire
    B.5.3.3Post codeSL7 1YL
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+44(0) 1628 494444
    B.5.5Fax number+44(0) 1628 494449
    B.5.6E-mailml-ctrg@allergan.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEluxadoline
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEluxadoline
    D.3.9.1CAS number 864821-90-9
    D.3.9.3Other descriptive nameELUXADOLINE
    D.3.9.4EV Substance CodeSUB175259
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboTablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Irritable Bowel Syndrome with
    Diarrhea (IBS-D)
    E.1.1.1Medical condition in easily understood language
    Abdominal pain / discomfort.
    Cramps, bloating , diarrhea and constipation.
    E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level PT
    E.1.2Classification code 10023003
    E.1.2Term Irritable bowel syndrome
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10060845
    E.1.2Term Diarrhea predominant irritable bowel syndrome
    E.1.2System Organ Class 10017947 - Gastrointestinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    - To explore the therapeutic effect of eluxadoline in treating IBS-D in pediatric participants 6-17 years of age.
    - To evaluate the pharmacokinetics (PK) of eluxadoline in pediatric patients with IBS-D.
    - To evaluate the safety and tolerability of eluxadoline in pediatric patients with IBS-D.
    E.2.2Secondary objectives of the trial
    The results of this dose-ranging study will allow the selection of an optimal dose(s) of eluxadoline to evaluate in the subsequent confirmatory efficacy study.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Participant must provide written or verbal informed assent and the parent/guardian/LAR and caregiver must provide written informed consent before the initiation of any study-specific procedures. 2. Participant is a male or female outpatient, 6 to 17 years of age inclusive, at the time the participant provides assent for the study and parent/guardian/LAR has provided signed consent. 3. Participant is able to read and understand the assessments in the eDiary. If the participant is 6 to 11 years of age and does not meet this criterion, the interviewer-administered version of the eDiary must be used and the parent/guardian/LAR or caregiver who will be administering the interviewer-administered version of the eDiary must be able to read and understand the assessments in the eDiary and must undergo training. 4. Female participants of childbearing potential must have a negative serum pregnancy test at Visit 1 (screening) and a negative urine pregnancy test at Visit 3 (randomization) prior to dosing. 5. Female participants who have had their first menstrual period and are sexually active must agree to use a reliable form of contraception. Reliable contraception is defined as: a) Hormonal contraception (eg, oral contraceptive, contraceptive implant, or injectable hormonal contraceptive). b) Double-barrier method (eg, condom plus intrauterine device, diaphragm plus spermicide). 6. Participant has a diagnosis of IBS D as defined by the modified Rome IV child/adolescent criteria*: Must include all of the following: 1. Abdominal pain at least 4 days per month over at least 2 months associated with one or more of the following: a. Related to defecation b. A change in frequency of stool c. A change in form (appearance) of stool 2. After appropriate evaluation, the symptoms cannot be fully explained by another medical condition 3. Participant has predominantly diarrheal stool symptoms defined as Bristol stool types 6 or 7 for >25% of bowel movements and Bristol stooltypes 1 or 2 for <25% of bowel movements that occur in the absence of laxatives *All criteria fulfilled for at least 2 months prior to Visit 1 (screening). 7. Participant has been compliant with the eDiary by completing both themorning and evening assessments for at least 8 out of the 14 days immediately preceding Visit 3 (randomization). 8. Participant has an average daytime abdominal pain score ≥2.0 over the 2 weeks prior to randomization. 9. Participant has at least 1 daytime bowel movement with a consistencyof Type 6 or Type 7 on the pediatric Bristol Stool Form Scale (p-BSFS) onat least 2 days per week during the 2 weeks prior to randomization that occurs in the absence of laxatives. 10. Participant has no clinically significant findings on a physical examination, vital sign assessment, electrocardiogram (ECG), and clinical laboratory tests (clinical chemistry panel, liver biochemical tests,
    complete blood count, urine drug screen, urinalysis) after providing informed assent and after written consent is obtained, but before receiving the first dose of study treatment. (A central laboratory will be used to evaluate all urine [except urine pregnancy tests] and blood samples and will utilize reference ranges specific to a participant's age and gender. ECGs will be performed and electronically transmitted to a central ECG laboratory for analysis by a pediatric cardiologist in accordance with the instructions provided by the central ECG laboratory. The Investigator will determine if a particular finding is clinically significant. [In making this determination, the Investigator will consider whether the particular finding could represent a condition that would exclude the participant from the study, could represent a safety concern if the participant participates in the study, or could confound the study-specific assessments of safety or efficacy.])
    E.4Principal exclusion criteria
    Participants who meet any of the following criteria will not be eligible to participate in the study: 1.has no gallbladder
    2.has had any of the following surgeries: a)Any abdominal surgery within the 3 months prior to trial; b)A history of major gastric, hepatic, pancreatic, or intestinal surgery 3.has known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction 4.has a history of pancreatitis; structural diseases of the pancreas, known or suspected pancreatic duct obstruction 5.has a history of cholecystitis within 6months before trial. 6.has known or suspected bile acid malabsorption. 7.is a current regular alcohol drinker and/or binge drinker, and/or has a history of alcoholism, alcohol abuse, or alcohol addiction, and/or intendsto consume alcohol during the trial. 8.has had chronic or severe constipation or sequelae from constipation, or known or suspected mechanical GI obstruction or pseudo obstruction.9.has had or current diagnosis of constipation with encopresis. 10.meets the child/adolescent Rome IV criteria of IBS with constipation,IBS with constipation and diarrhea (mixed), unspecified IBS, or functional constipation. 11.has had intestinal obstruction, stricture, toxic megacolon, GI perforation, fecal impaction, gastric banding, bariatric surgery, adhesions, ischemic colitis, or impaired intestinal circulation. 12.has a history of hepatic impairment as defined by Child-Pugh Classification Grade A,B or C 13.has a history or current diagnosis of inflammatory or immune-mediated lower GI disorders including inflammatory bowel disease 14.has celiac disease,or a positive serological test for celiac disease and the condition has not been ruled out by endoscopic biopsy 15.has any congenital and/or acquired malabsorption syndrome 16.has a history of a microbiologically documented GI infection within 3 months prior to trial 17.has a known lactose or fructose intolerance 18.has a history of diverticulitis within 3 months prior to trial 19.has had within 5 years prior to trial or current evidence of laxative abuse 20.has a history of either hypo-or hyperthyroidism that is untreated or treated with medication at a dose that has not been stable for at least 3 months prior to trial. 21.Participant's diarrhea is deemed by the Investigator to be caused by infectious 22.has had or current evidence of blood in the stool 23.currently has both unexplained and clinically significant alarm symptoms and systemic signs of infection or colitis, or any neoplastic process 24.has a history or current diagnosis of eosinophilic gastroenteritis 25.has Cystic Fibrosis, and or any other causes of pancreatic exocrine insufficiency 26.is receiving enteral tube feeding 27.has a history of a cardiovascular event, including stroke, myocardial infarction, congestive heart failure, or transient ischemic attack within 6months prior to trial 28. has renal impairment or an unstable hepatic, metabolic, or hematologic condition 29.has a history of malignancy within 5 years before Screening, which includes any new diagnosis of malignancy or any treatment for or recurrence of a malignancy that was diagnosed 5 or more years prior. In order to be eligible for the study, participant must be malignancy free forthe past 5 years 30.has a history of immunodeficiency 31.has a history of drug abuse 32.has a positive urine drug result 33.has a weight and BMI less than the 3rd percentile. 34.has had an unintentional weight loss greater than or equal to 5% of his/her body weight within the last 3months 35.Female participants who are pregnant or nursing, or plan to become pregnant or nurse during the trial 36.has known allergies or hypersensitivity to opioids 37.used a prohibited medication or failed to meet the stabledose 38.is unable to tolerate the placebo oral tablets prior to randomization.39.has any condition that, in the opinion of the Investigator, would contribute to the participant's IBS-D symptoms or confound the evaluation of safety or efficacy of the IMP 40.has neurodevelopmental disabilities producing a cognitive delay that precludes comprehension and completion of the daily eDiary or other study-related questionnaires 41.has a poorly treated or poorly controlled psychiatric disorder that might influence the participant's ability to participate in the study 42.has an acute or chronic condition that, in the Investigator's opinion, would limit the participants' ability to complete or participate in this clinical study 43.has any condition that, in the opinion of the Investigator, would compromise the well-being of the participant 44.received an investigational product during the 30 days before Visit1 or is planning to receive an IMP or use an investigational device at anytime during the study 45. Participant's parent/guardian/LAR has been directly or indirectly involved in the conduct and administration of this study
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy assessment will be the change from baseline in the 24-hour (combined daytime and nighttime) daily stool consistency averaged over the 4-week Treatment Period.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Throughout the study
    Over the 4-week period
    E.5.2Secondary end point(s)
    The secondary change-from-baseline efficacy parameters include change from baseline in the 4 week average for daily daytime stool consistency scores and for nighttime stool consistency. scores, separately, during the Treatment Period. Additional, secondary change from baseline efficacy parameters include change from baseline in the 4 week average for daytime, nighttime and 24 hour (combined daytime and nighttime),) abdominal pain severity, bowel movement frequency, and urgency-free days in a week, and number of fecal incontinence-free days in a week during the Treatment Period. The secondary efficacy parameters evaluating change-from-baseline will be analyzed using an ANCOVA model similar to the one defined for the primary efficacy parameter.
    E.5.2.1Timepoint(s) of evaluation of this end point
    throughout the study
    4 week
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response Yes
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Dose Ranging
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA56
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Canada
    United States
    Bulgaria
    Hungary
    Netherlands
    Poland
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of Trial is defined by the Last Patient Last visit
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days23
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months3
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 120
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.5.1Number of subjects for this age range: 24
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 96
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state3
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 50
    F.4.2.2In the whole clinical trial 120
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No treatment will be given to the participants after the study has ended
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2018-08-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-02-11
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Apr 19 08:39:15 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA